NJ
Therapeutic Areas
Esperion Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NEXLETOL (bempedoic acid) | Heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering | Approved |
| NEXLIZET (bempedoic acid and ezetimibe) | Heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering | Approved |
| Bempedoic Acid | Cardiovascular Risk Reduction (in statin-intolerant patients) | Phase 3 |
Leadership Team at Esperion Therapeutics
SK
Sheldon Koenig
President, Chief Executive Officer and Director
BL
Benjamin Looker
Chief Financial Officer and Treasurer
JM
JoAnne M. Foody
Chief Medical Officer
TM
Timothy M. Mayleben
Chief Operating Officer and Chief Commercial Officer
MG
Mark G. Foletta
Senior Vice President, Chief Accounting Officer and Controller
AH
Ashley Hall
Senior Vice President, General Counsel and Corporate Secretary
WH
William H. Lewis
Chairman of the Board of Directors
AG
Andrew G. Bodnar
Director
RB
Richard B. Bartram
Director
TP
Timothy P. Walbert
Director